Lilly/PDI Chasing 25% Evista Growth: Short In Q1, But Some Positive Signs
Lilly and PDI are aiming at a 25% growth target for Evista (raloxifene) as part of the co-promotion of the osteoporosis drug, PDI CEO Charles Saldarini told investors May 14
Lilly and PDI are aiming at a 25% growth target for Evista (raloxifene) as part of the co-promotion of the osteoporosis drug, PDI CEO Charles Saldarini told investors May 14